Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy

M V Maevskaya; V T Ivashkin; K V Ivashkin; V D Lunkov; E O Liusina; V N Zozula; V I Leshchenko

doi:10.26442/00403660.2019.02.000122

Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy

Ter Arkh. 2019 Mar 18;91(2):109-117. doi: 10.26442/00403660.2019.02.000122.

Authors

M V Maevskaya¹, V T Ivashkin¹, K V Ivashkin¹, V D Lunkov¹, E O Liusina¹, V N Zozula¹, V I Leshchenko¹

Affiliation

¹ I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.

PMID: 31094181
DOI: 10.26442/00403660.2019.02.000122

Abstract

The article presents an update of the role of non-alcoholic fatty liver disease (NAFLD) in cardiometabolic diseases and events: arterial hypertension and components of the metabolic syndrome. A review of NAFLD modern pharmacotherapy has been conducted. Particular attention is paid to the place of ursodeoxycholic acid in the complex treatment of NAFLD.

Keywords: arterial hypertension; insulin resistance; non-alcoholic fatty liver disease; ursodeoxycholic acid.

Publication types

Review

MeSH terms

Cholagogues and Choleretics / therapeutic use*
Humans
Hypertension / complications*
Metabolic Syndrome / complications*
Non-alcoholic Fatty Liver Disease / complications
Non-alcoholic Fatty Liver Disease / drug therapy*
Risk Factors
Ursodeoxycholic Acid / therapeutic use*

Substances

Cholagogues and Choleretics
Ursodeoxycholic Acid